KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Free Cash Flow (2016 - 2026)

Gilead Sciences filings provide 17 years of Free Cash Flow readings, the most recent being $3.1 billion for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 10.4% to $3.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 billion, a 8.24% decrease, with the full-year FY2025 number at $9.5 billion, down 8.24% from a year prior.
  • Free Cash Flow hit $3.1 billion in Q4 2025 for Gilead Sciences, down from $4.0 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $4.2 billion in Q3 2024 to a low of $720.0 million in Q2 2025.
  • Median Free Cash Flow over the past 5 years was $2.2 billion (2021), compared with a mean of $2.3 billion.
  • The widest YoY moves for Free Cash Flow: up 155.24% in 2024, down 45.66% in 2024.
  • Gilead Sciences' Free Cash Flow stood at $3.0 billion in 2021, then decreased by 21.74% to $2.4 billion in 2022, then fell by 18.11% to $2.0 billion in 2023, then skyrocketed by 44.73% to $2.8 billion in 2024, then increased by 10.4% to $3.1 billion in 2025.
  • The last three reported values for Free Cash Flow were $3.1 billion (Q4 2025), $4.0 billion (Q3 2025), and $720.0 million (Q2 2025) per Business Quant data.